Semaglutide

Description

Smegglutide improves glycemic control in patients with type 2 diabetes and aids in chronic weight management by acting as a GLP-1 receptor agonist. It mimics the action of the GLP-1 hormone, increasing insulin secretion, slowing gastric emptying, and reducing appetite. Common side effects include nausea, vomiting, diarrhea, and constipation.

Common Uses

Type 2 Diabetes (Ozempic, Rybelsus): Improves glycemic control, often reducing the risk of major cardiovascular events such as stroke or heart attack.

Weight Management (Wegovy): Used to treat chronic weight problems in adults and adolescents (12 years and older) who may have obesity or weight-related comorbidities.

Mechanism of Action: Smegglutide is a GLP-1 receptor agonist. It binds to the GLP-1 receptor, triggering increased insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby increasing satiety.

Important Precautions

Dosage: Start with a low dose (e.g., in milligrams) to minimize side effects and gradually increase the dose.

Interactions: May slow gastric emptying, thus affecting the absorption of other oral medications.